Literature DB >> 25801839

Lewy Bodies: A Spectator or Salient Killer?

Jeswinder Sian-Hulsmann, Camelia Monoranu, S Strobel, Peter Riederer1.   

Abstract

Lewy bodies (LBs) are characteristic hallmarks of Parkinson's disease (PD). However, their role in the pathology of PD is not established yet. Are they primary events in the neurodegenerative process or only secondary phenomena? Are they signs of protecting neurons from toxicity or are they toxic per se? How are they are formed? Are LBs targets for therapeutic strategies? Addressing these questions may be of pivotal importance to unravel the basic mechanisms of neurodegeneration in PD. On the basis of current evidence, we intend to elucidate the possible role of LBs as triggers and/or markers of disease progression in PD. We present evidence for the morphogenesis of brain stem and cortical LBs, the role in neuronal cell death mechanisms, which seem to be correlated with the adhesion of LBs to and finally disruption of their inner neuronal membrane. Taken as such, LBs would be salient killers of nerve cells. However, they may also play a neuroprotective role in the early phases of neuronal pathology (LBs as a spectator), yet harmful to neuronal stability in later stages of LB development. Generation of LB pathology in the periphery (early subclinical Braak stage) might be due to reactive oxygen species (ROS) due to (chronic) bacteria-induced and/or otherwise intestinal inflammation, both leading to alpha-synuclein structural changes, oligomerization, seeding and propagation in a prion-like mechanism. If so, LB generation is a secondary process following ROS/inflammation pathology. Therapeutic implication based on LB pathology include drug development to inhibit protein misfolding, templating and transmission or vaccination against LBs, neuron regeneration strategies, anti-inflammatory and anti-biotic drugs as well as nutritional specialities to prevent intestine intoxications. In conclusion, evidence suggests LBs to be secondary hallmarks of PD pathology, induced by ROS/inflammation or other pathological triggers able to modify protein (alpha-synuclein) steric/chemical properties. Therapeutic strategies based on LB pathologies are devoted to reduce neuron cell death mechanisms in their time course and severity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801839     DOI: 10.2174/1871527314666150317225659

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  13 in total

Review 1.  Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.

Authors:  Peter Riederer; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-03-22       Impact factor: 3.575

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 3.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

4.  A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease.

Authors:  Morgan Bérard; Razan Sheta; Sarah Malvaut; Raquel Rodriguez-Aller; Maxime Teixeira; Walid Idi; Roxanne Turmel; Melanie Alpaugh; Marilyn Dubois; Manel Dahmene; Charleen Salesse; Jérôme Lamontagne-Proulx; Marie-Kim St-Pierre; Omid Tavassoly; Wen Luo; Esther Del Cid-Pellitero; Raza Qazi; Jae-Woong Jeong; Thomas M Durcan; Luc Vallières; Marie-Eve Tremblay; Denis Soulet; Martin Lévesque; Francesca Cicchetti; Edward A Fon; Armen Saghatelyan; Abid Oueslati
Journal:  PLoS Biol       Date:  2022-03-09       Impact factor: 8.029

Review 5.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

6.  Nanomolar oligomerization and selective co-aggregation of α-synuclein pathogenic mutants revealed by single-molecule fluorescence.

Authors:  Emma Sierecki; Nichole Giles; Quill Bowden; Mark E Polinkovsky; Janina Steinbeck; Nicholas Arrioti; Diya Rahman; Akshay Bhumkar; Philip R Nicovich; Ian Ross; Robert G Parton; Till Böcking; Yann Gambin
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

7.  Editorial Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives.

Authors:  Thomas Müller
Journal:  Neurol Ther       Date:  2018-04-27

Review 8.  Molecular Imaging of the Dopamine Transporter.

Authors:  Giovanni Palermo; Roberto Ceravolo
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

Review 9.  View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?

Authors:  Thomas Müller
Journal:  Biologics       Date:  2021-07-29

10.  Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases.

Authors:  Douglas G Walker; Lih-Fen Lue; Geidy Serrano; Charles H Adler; John N Caviness; Lucia I Sue; Thomas G Beach
Journal:  Front Neurosci       Date:  2016-01-14       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.